SCHEMBL30795463

SCHEMBL30795463

CC(C)CNc1ccc(NC(=O)Cc2cc(F)cc(F)c2)c(N2CCCC2)n1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNQ2 O43526 7/20 0.44
PSEN1 P49768 7/20 0.41
PSEN2 P49810 7/20 0.41
APH1B Q8WW43 7/20 0.41
NCSTN Q92542 7/20 0.41
APH1A Q96BI3 7/20 0.41
PSENEN Q9NZ42 7/20 0.41
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
KCNQ3 O43525 1/20 0.38
GAA P10253 2/20 0.37
PKM P14618 1/20 0.37
CACNA1H O95180 1/20 0.36
BRPF1 P55201 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1172601 1.00 KCNQ2 (0.44) KCNQ2PSEN1PSEN2APH1BNCSTN
SCHEMBL30796321 0.85 KCNQ2 (0.49) KCNQ2KMT2AMEN1TRPV1KCNQ3
SCHEMBL1172488 0.85 KCNQ2 (0.49) KCNQ2KMT2AMEN1TRPV1KCNQ3
SCHEMBL1172904 0.85 KCNQ2 (0.46) KCNQ2KMT2AMEN1TRPV1KCNQ3
SCHEMBL30795010 0.85 KCNQ2 (0.46) KCNQ2KMT2AMEN1TRPV1KCNQ3
SCHEMBL30796352 0.83 KCNQ2 (0.52) KCNQ2KMT2ATRPV1CACNA1H
SCHEMBL13810507 0.83 KCNQ2 (0.45) KCNQ2KMT2AMEN1TRPV1KCNQ3
SCHEMBL1172456 0.83 KCNQ2 (0.52) KCNQ2KMT2ATRPV1CACNA1H
SCHEMBL1172354 0.82 KCNQ2 (0.49) KCNQ2KMT2AMEN1GAACACNA1H
SCHEMBL30795229 0.82 KCNQ2 (0.49) KCNQ2KMT2AMEN1GAACACNA1H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed